返回 
加入收藏
脑心通胶囊联合依达拉奉治疗急性脑梗死的疗效分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 脑心通胶囊联合依达拉奉治疗急性脑梗死的疗效分析 |
| TITLE： | |
| 摘要： | 目的：探讨脑心通胶囊联合依达拉奉治疗急性脑梗死的疗效和安全性。方法：回顾性分析80例急性脑梗死患者资料，按用药的不同分为观察组（40例）和对照组（40例）。两组患者均给予阿司匹林肠溶片10 mg，口服，每日1次，以抗血小板聚集；20％甘露醇注射液250 mL，静脉滴注，每12 h 1次，以控制脑水肿；氯化钾缓释片0.5 g，口服，每日3次，以维持水电解质平衡等常规治疗。在此基础上，对照组患者给予依达拉奉注射液30 mg，加入0.9％氯化钠注射液100 mL中，静脉滴注，每日1次，30 min内滴完；观察组患者在对照组治疗的基础上给予脑心通胶囊1.6 g，口服，每日3次。两组疗程均为10 d。观察两组患者的临床疗效，治疗前后内皮素1（ET-1）、一氧化氮（NO）含量、白细胞介素8（IL-8）、超敏C反应蛋白（hs-CRP）、游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）、促甲状腺激素（TSH）水平、神经功能缺损程度（NIHSS）、日常生活能力（ADL）评分及不良反应发生情况。结果：观察组患者总有效率显著高于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者ET-1、NO含量，IL-8、hs-CRP、FT3、FT4 、TSH水平，NIHSS及ADL评分比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者ET-1含量，IL-8、hs-CRP水平及NIHSS评分均显著低于同组治疗前，且观察组显著低于对照组；两组患者NO含量、TSH水平、ADL评分均显著高于同组治疗前，且观察组显著高于对照组，差异均有统计学意义（P＜0.05）；两组患者治疗前后FT3、FT4水平比较，差异均无统计学意义（P＞0.05）。两组患者用药期间均未见严重不良反应发生。结论：在常规治疗的基础上，脑心通胶囊联合依达拉奉治疗急性脑梗死可提高疗效，改善血管内皮功能、减轻炎症反应、降低TSH水平，且未增加不良反应的发生。 |
| ABSTRACT： | OBJECTIVE： To investigate therapeutic efficacy and safety of Naoxintong capsules combined with edaravone in the treatment of acute cerebral infarction. METHODS： 80 patients with acute cerebral infarction were analyzed retrospectively and divided into observation group （40 cases） and control group （40 cases） according to drug use. Both groups was given Aspirin enteric-coated tablets 10 mg orally， once a day， to control platelet aggregation，20％ Mannitol injection 250 mL intravenously， every 12 hours， to control brain edema，Potassium chloride sustained-release tablets 0.5 g orally， 3 times a day， to maintain water and electrolyte balance and other conventional treatment. Control group was additionally given Edaravone injection 30 mg added into 0.9％ Sodium chloride injection 100 mL intravenously within 30 min， once a day； observation group was additionally given Naoxintong capsules 1.6 g， 3 times a day on the basis of control group. Treatment course of both groups lasted for 10 d. Clinical efficacies of 2 groups were observed as well as the ET-1 and NO content， IL-8， hs-CRP， FT3， FT4 and TSH level， NIHSS and ADL score， the occurrence of ADR before and after treatment. RESULTS： Total response rate of observation group was significantly higher than that of control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in the ET-1 and NO content， IL-8， hs-CRP， FT3， FT4 and TSH level， NIHSS and ADL score between 2 groups （P＞0.05）. After treatment， the ET-1 content， IL-8 and hs-CRP level， NIHSS score in 2 groups were significantly lower than before， and the observation group was lower than the control group； the NO content， TSH， ADL score in 2 groups were significantly higher than before， and the observation groups was higher than the control group， with statistical significance （P＜0.05）. There was no statistical significance in the levels of FT3 and FT4 between 2 groups before and after treatment （P＞0.05）. No severe ADR was found in 2 groups. CONCLUSIONS： Based on routine treatment， Naoxintong capsules combined with edaravone in the treatment of acute cerebral infarction can improve therapeutic efficacy and vascular endothelial function， relieve inflammatory reaction and recue TSH levels， moreover， don’t increase the occurrence of ADR. |
| 期刊： | 2017年第28卷第9期 |
| 作者： | 武胜涛，张羽，李富慧 |
| AUTHORS： | WU Shengtao，ZHANG Yu，LI Fuhui |
| 关键字： | 脑心通胶囊；依达拉奉；急性脑梗死；疗效；安全性 |
| KEYWORDS： | Naoxintong capsules； Edaravone； Acute cerebral infarction； Efficacy； Safety |
| 阅读数： | 313 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
